A Phase 2 interventional study of EDP-938 and Placebo in RSV Infection, sponsored by Enanta Pharmaceuticals, Inc. Completed at 84 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Enanta Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections — 1 open to participants now, 1 under way, none of them phase 3. EDP-938 · Respiratory Syncytial Virus Infections.
Among the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, this one has the largest enrollment, is the only one that started in 2022, is one of 4 in phase 2, and was the 8th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:
Enanta Pharmaceuticals, Inc · Sites in Thailand
Ages 28 days–36 mo
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 187 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 81 across the 10 interventional studies. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
Enanta Pharmaceuticals, Inc is the lead sponsor of 46 studies on the registry; 3 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc: 1 open now, 1 under way, none of them phase 3. Of 13 finished, 4 (31%) have results posted.
Among the 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc, this one has the largest enrollment, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 8th registered.
Enanta Pharmaceuticals, Inc’s Respiratory Syncytial Virus Infections studies by the year they started, since 2017.
1 of the studies testing EDP-938 in Respiratory Syncytial Virus Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482657Enanta Pharmaceuticals, IncA Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Enanta Pharmaceuticals, Inc’s 14 in Respiratory Syncytial Virus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who were at high risk for complications after RSV infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least one of the following conditions that predispose them to complications after RSV infection:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EDP-938 800 mg, once daily
Drug: EDP-938
Matching placebo, once daily
Drug: Placebo
Subjects took EDP-938 once daily for 5 days
Subjects took matching placebo, once daily for 5 days
Time to Resolution of RSV Lower Respiratory Tract Disease (LRTD) Symptoms
Resolution of LRTD Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) as assessed by RiiQTM Scale Score is zero or 1. Time to resolution of LRTD symptoms is calculated as: date/time of resolution - date/time of first dose with conversion to days.
Time frame: Day 1 through Day 33
Time to Complete Resolution of LRTD Symptoms for the mITT Population
Complete resolution of LRTD Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) as assessed by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Scale Score is zero. Time to complete resolution of LRTD symptoms is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.
Time frame: Day 1 through Day 33
Time to Complete Resolution of LRTD Symptoms for the HR3 Population
Complete resolution of LRTD Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) as assessed by RiiQTM Scale Score is zero. Time to complete resolution of LRTD symptoms is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.
Time frame: Day 1 through Day 33
Time to Resolution of LRTD Symptoms and 2 Systemic Symptoms
Resolution of LRTD and 2 Systemic Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) and each of the 2 systemic symptoms (feeling fever and fatigue/tiredness) as assessed by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Scale Score is zero or 1; Higher scores indicate worse outcomes (greater symptom intensity and greater impact on daily functioning). Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.
Time frame: Day 1 through Day 33
Time to Resolution of All RSV Symptoms
Resolution of all RSV Symptoms is defined as the first of two consecutive timepoints where each of the 13 RSV symptoms as assessed by RiiQ Scale Score is zero or 1. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.
Time frame: Day 1 through Day 33
Time to Complete Resolution of All RSV Symptoms for the mITT Population
Complete resolution of all RSV Symptoms is defined as the first of two consecutive timepoints where each of the 13 RSV symptoms as assessed by RiiQTM Scale Score is zero. Time to complete resolution is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.
Time frame: Day 1 through Day 33
Time to Complete Resolution of All RSV Symptoms for the HR3 Population
Complete resolution of all RSV Symptoms is defined as the first of two consecutive timepoints where each of the 13 RSV symptoms as assessed by RiiQTM Scale Score is zero. Time to complete resolution is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.
Time frame: Day 1 through Day 33
Change From Baseline in Severity of RSV LRTD Symptoms
The RiiQ Infection Intensity Scale assesses 4 symptoms of LRTD (cough, shortness of breath, wheezing, and expectoration) on a scale from 0 (absent) to 3 (severe). The composite LRTD Score is the average of all 4 individual item scores.
Time frame: Day 1 through Day 33
Change From Baseline for Impact Scale
The RiiQ Impact Scale assesses daily activities (7 items), emotions (4 items), and social relationships (5 items) on a scale of 0 (no impact) to 3 (extreme impact). The composite Impact Score is the average of all 16 individual item scores.
Time frame: Day 1 through Day 33
Time to Resolution of Upper Respiratory Tract Disease Congestion, LRTD, and 2 Systemic Symptoms
Resolution of Symptoms is defined as the first of two consecutive timepoints where each of the RSV symptoms (4 LRTD symptoms \[cough, short of breath, wheezing, coughing up phlegm \[sputum\]\], 2 URTD symptoms \[nasal congestion and sore throat\], 2 Systemic symptoms \[feeling feverish and fatigue\[tiredness\]\]) as assessed by RiiQTM Scale Score is zero or 1. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.
Time frame: Day 1 through Day 33
Time to no or Mild Impact of RSV Disease on Daily Activities, Emotions, and Social Relationships
Resolution of No or Mild Impact of RSV is defined as the first of two consecutive timepoints where each of the 3 impact Scale Scores (daily activities, emotions and social relationships) as assessed by RiiQTM Scale Score is zero or 1. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.
Time frame: Day 1 through Day 33
Percentage of Participants With Post-baseline RSV-related Complications
Time frame: Day 1 through Day 33
Time to Improvement in RSV Disease
Time to Improvement is defined as the time from first dose to first timepoint where the response assessed by PGI-C is 'Much better'. Time to Improvement is calculated as: date/time of Improvement - date/time of first timepoint.
Time frame: Day 1 through Day 33
Change From Baseline for Health-Related Quality of Life
Assessed by EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire; 5 dimensions (mobility, taking care of yourself, usual activities, pain/discomfort, and anxiety/depression) are scored on 5 levels from 1 (full health) to 5 (extreme disability). An index score is derived based on the 5 reported levels where 1.0 represents full health and 0.0 the worst possible health.
Time frame: Day 1 through Day 33
Time to Return to Usual Health
Time to return to usual health is defined as the time from first dose to first timepoint where the response as assessed by Adult Return to Usual Health is 'Yes'. Time to return to usual health is calculated as: date/time of return to usual health - date/time of response to 'Yes'.
Time frame: Day 1 through Day 33
Time to Return to Usual Activities
Time to return to usual activities is defined as the time from first dose to first timepoint where the response as assessed by Adult Return to Usual Activities is 'Yes'. Time to return to usual activities is calculated as: date/time of return to usual activities - date/time of first response to 'Yes'.
Time frame: Day 1 through Day 33
Percentage of Subjects Requiring Hospitalization for RSV or Other Causes
Time frame: Day 1 through Day 33
Duration of Hospitalization for RSV or Other Causes
Time frame: Day 1 through Day 33
All-cause Mortality
Time frame: Day 1 through Day 33
RSV RNA Viral Load Change From Baseline for the mITT Population
Time frame: Days 3, 5, 9, and 14
Change in Infectious RSV Viral Load Over Time
Time frame: Up to Day 14
Proportion of Subjects With RSV RNA Viral Load Target Not Detected (TND) for the mITT Population
Time frame: Days 1, 3, 5, 9 and 14
Time to RSV RNA Viral Load TND for the mITT Population
Time to RSV viral load TND is defined as the time between the date of first dose to the first date of achieving viral load TND.
Time frame: Day 1 through Day 14
Plasma PK Concentrations of EDP-938
Time frame: Up to Day 5
Safety as Measured by Frequency of Adverse Events (AEs)
Number of subjects experiencing any Treatment-Emergent Adverse Events (TEAEs)
Time frame: Up to Day 33
Time to Resolution of RSV Infection Symptoms by Patient Global Impression of Severity (PGI-S) Scale Score for the mITT Population
PGI-S is a 7-point patient-reported scale ranging from 1 (normal/none) to 7 (among the most extremely ill); lower scores indicate less severe disease. Time to resolution is defined as time from the first dose to first of two consecutive timepoints where the response assessed by PGI-S is 'None'. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.
Time frame: Day 1 through Day 33
Incidence of New Antibiotic Use, or New or Increased Use of Bronchodilators, Systemic or Inhaled Corticosteroids, or Oxygen Supplementation for the mITT Population
Incidence was defined as the number of subjects with new antibiotic, bronchodilators, inhaled corticosteroids or oxygen use
Time frame: Day 1 through Day 33
Incidence of Unscheduled Medically Attended Visits for RSV Infection or Other Causes for the mITT Population
Incidence was defined as the number of subjects with unscheduled medically attended visits for RSV infection or other causes.
Time frame: Day 1 through Day 33
| Milestone | EDP-938 | Placebo |
|---|---|---|
| Started | 123 | 64 |
| Completed | 116 | 60 |
| Not completed | 7 | 4 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 2 |
| Withdrew: Death | 0 | 1 |
Resolution of LRTD Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) as assessed by RiiQTM Scale Score is zero or 1. Time to resolution of LRTD symptoms is calculated as: date/time of resolution - date/time of first dose with conversion to days.
| days | EDP-938 | Placebo |
|---|---|---|
| Time to Resolution of RSV Lower Respiratory Tract Disease (LRTD) Symptoms | 5.0 (4.0 to 7.0) | 4.1 (3.0 to 5.9) |
Complete resolution of LRTD Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) as assessed by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Scale Score is zero. Time to complete resolution of LRTD symptoms is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.
| Days | EDP-938 | Placebo |
|---|---|---|
| Time to Complete Resolution of LRTD Symptoms for the mITT Population | 12.5 (11.2 to 15.3) | 13.0 (9.6 to 19.0) |
Complete resolution of LRTD Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) as assessed by RiiQTM Scale Score is zero. Time to complete resolution of LRTD symptoms is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.
| Days | EDP-938 | Placebo |
|---|---|---|
| Time to Complete Resolution of LRTD Symptoms for the HR3 Population | 12.0 (10.0 to 15.2) | 15.0 (9.9 to 20.0) |
Resolution of LRTD and 2 Systemic Symptoms is defined as the first of two consecutive timepoints where each of the four LRTD symptoms (cough, short of breath, wheezing and coughing up phlegm\[sputum\]) and each of the 2 systemic symptoms (feeling fever and fatigue/tiredness) as assessed by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Scale Score is zero or 1; Higher scores indicate worse outcomes (greater symptom intensity and greater impact on daily functioning). Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.
| days | EDP-938 | Placebo |
|---|---|---|
| Time to Resolution of LRTD Symptoms and 2 Systemic Symptoms | 5.0 (4.1 to 6.0) | 5.0 (3.0 to 6.0) |
Resolution of all RSV Symptoms is defined as the first of two consecutive timepoints where each of the 13 RSV symptoms as assessed by RiiQ Scale Score is zero or 1. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.
| days | EDP-938 | Placebo |
|---|---|---|
| Time to Resolution of All RSV Symptoms | 5.9 (5.0 to 6.8) | 5.0 (4.8 to 7.1) |
Complete resolution of all RSV Symptoms is defined as the first of two consecutive timepoints where each of the 13 RSV symptoms as assessed by RiiQTM Scale Score is zero. Time to complete resolution is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.
| Days | EDP-938 | Placebo |
|---|---|---|
| Time to Complete Resolution of All RSV Symptoms for the mITT Population | 13.8 (12.0 to 16.1) | 16.0 (12.0 to 23.0) |
Complete resolution of all RSV Symptoms is defined as the first of two consecutive timepoints where each of the 13 RSV symptoms as assessed by RiiQTM Scale Score is zero. Time to complete resolution is calculated as: date/time of complete resolution - date/time of first dose with conversion to days.
| Days | EDP-938 | Placebo |
|---|---|---|
| Time to Complete Resolution of All RSV Symptoms for the HR3 Population | 12.2 (11.1 to 16.1) | 18.9 (13.0 to 24.7) |
The RiiQ Infection Intensity Scale assesses 4 symptoms of LRTD (cough, shortness of breath, wheezing, and expectoration) on a scale from 0 (absent) to 3 (severe). The composite LRTD Score is the average of all 4 individual item scores.
| RiiQ Scale Score | EDP-938 | Placebo |
|---|---|---|
| Day 2 | -0.320 ± 0.5362 | -0.315 ± 0.5056 |
| Day 3 | -0.411 ± 0.5411 | -0.513 ± 0.6168 |
| Day 5 | -0.815 ± 0.6400 | -0.811 ± 0.5830 |
| Day 7 | -1.052 ± 0.6785 | -1.022 ± 0.7043 |
| Day 9 | -1.165 ± 0.7136 | -1.086 ± 0.7427 |
| Day 14 | -1.376 ± 0.6785 | -1.327 ± 0.6699 |
| Day 33 | -1.439 ± 0.7911 | -1.473 ± 0.7378 |
The RiiQ Impact Scale assesses daily activities (7 items), emotions (4 items), and social relationships (5 items) on a scale of 0 (no impact) to 3 (extreme impact). The composite Impact Score is the average of all 16 individual item scores.
| Impact Scale Score | EDP-938 | Placebo |
|---|---|---|
| Day 2 | -0.314 ± 0.5568 | -0.229 ± 0.6998 |
| Day 3 | -0.415 ± 0.6554 | -0.434 ± 0.7848 |
| Day 5 | -0.640 ± 0.6847 | -0.592 ± 0.7620 |
| Day 7 | -0.864 ± 0.8279 | -0.707 ± 0.8685 |
| Day 9 | -1.001 ± 0.9005 | -0.786 ± 0.9597 |
| Day 14 | -1.001 ± 0.8945 | -0.940 ± 0.8526 |
| Day 33 | -1.154 ± 0.8800 | -1.130 ± 0.8767 |
Resolution of Symptoms is defined as the first of two consecutive timepoints where each of the RSV symptoms (4 LRTD symptoms \[cough, short of breath, wheezing, coughing up phlegm \[sputum\]\], 2 URTD symptoms \[nasal congestion and sore throat\], 2 Systemic symptoms \[feeling feverish and fatigue\[tiredness\]\]) as assessed by RiiQTM Scale Score is zero or 1. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.
| days | EDP-938 | Placebo |
|---|---|---|
| Time to Resolution of Upper Respiratory Tract Disease Congestion, LRTD, and 2 Systemic Symptoms | 5.8 (5.0 to 6.2) | 5.0 (4.0 to 6.1) |
Resolution of No or Mild Impact of RSV is defined as the first of two consecutive timepoints where each of the 3 impact Scale Scores (daily activities, emotions and social relationships) as assessed by RiiQTM Scale Score is zero or 1. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.
| days | EDP-938 | Placebo |
|---|---|---|
| Time to no or Mild Impact of RSV Disease on Daily Activities, Emotions, and Social Relationships | 3.0 (2.0 to 3.0) | 2.0 (1.9 to 4.0) |
| Participants | EDP-938 | Placebo |
|---|---|---|
| Percentage of Participants With Post-baseline RSV-related Complications | 5 | 3 |
Time to Improvement is defined as the time from first dose to first timepoint where the response assessed by PGI-C is 'Much better'. Time to Improvement is calculated as: date/time of Improvement - date/time of first timepoint.
| days | EDP-938 | Placebo |
|---|---|---|
| Time to Improvement in RSV Disease | 5.0 (4.0 to 6.0) | 6.0 (4.0 to 7.0) |
Assessed by EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire; 5 dimensions (mobility, taking care of yourself, usual activities, pain/discomfort, and anxiety/depression) are scored on 5 levels from 1 (full health) to 5 (extreme disability). An index score is derived based on the 5 reported levels where 1.0 represents full health and 0.0 the worst possible health.
| EQ-5D 5L Score | EDP-938 | Placebo |
|---|---|---|
| Day 5 | 0.108 ± 0.1836 | 0.083 ± 0.1407 |
| Day 9 | 0.207 ± 0.2030 | 0.152 ± 0.1679 |
| Day 14 | 0.210 ± 0.2142 | 0.169 ± 0.1549 |
| Day 33 | 0.233 ± 0.1951 | 0.182 ± 0.1544 |
Time to return to usual health is defined as the time from first dose to first timepoint where the response as assessed by Adult Return to Usual Health is 'Yes'. Time to return to usual health is calculated as: date/time of return to usual health - date/time of response to 'Yes'.
| days | EDP-938 | Placebo |
|---|---|---|
| Time to Return to Usual Health | 8.0 (6.1 to 10.0) | 8.0 (6.0 to 10.7) |
Time to return to usual activities is defined as the time from first dose to first timepoint where the response as assessed by Adult Return to Usual Activities is 'Yes'. Time to return to usual activities is calculated as: date/time of return to usual activities - date/time of first response to 'Yes'.
| days | EDP-938 | Placebo |
|---|---|---|
| Time to Return to Usual Activities | 6.0 (5.0 to 7.0) | 6.5 (5.0 to 8.0) |
| Participants | EDP-938 | Placebo |
|---|---|---|
| Percentage of Subjects Requiring Hospitalization for RSV or Other Causes | 2 | 3 |
| days | EDP-938 | Placebo |
|---|---|---|
| Duration of Hospitalization for RSV or Other Causes | 3.5 (3.0 to 4.0) | 7.0 (5.0 to 11.0) |
| Participants | EDP-938 | Placebo |
|---|---|---|
| All-cause Mortality | 0 | 1 |
| RSV viral load (log10 copies/mL) | EDP-938 | Placebo |
|---|---|---|
| Day 3 | -1.199 ± 0.1757 | -0.803 ± 0.2417 |
| Day 5 | -2.153 ± 0.2107 | -1.561 ± 0.2895 |
| Day 9 | -3.698 ± 0.2289 | -3.401 ± 0.3072 |
| Day 14 | -4.424 ± 0.1985 | -4.326 ± 0.2635 |
| RSV Viral Load (log10 TCID50/ml) | EDP-938 | Placebo |
|---|---|---|
| Day 3 | -0.590 ± 1.4789 | -0.517 ± 1.5516 |
| Day 5 | -0.656 ± 1.4389 | -0.836 ± 1.7683 |
| Day 9 | -0.662 ± 1.4442 | -0.937 ± 1.6041 |
| Day 14 | -0.664 ± 1.4534 | -0.908 ± 1.6033 |
| Participants | EDP-938 | Placebo |
|---|---|---|
| Day 1 | 4 | 3 |
| Day 3 | 14 | 5 |
| Day 5 | 27 | 6 |
| Day 9 | 55 | 26 |
| Day 14 | 70 | 36 |
Time to RSV viral load TND is defined as the time between the date of first dose to the first date of achieving viral load TND.
| Days | EDP-938 | Placebo |
|---|---|---|
| Time to RSV RNA Viral Load TND for the mITT Population | 8.0 (7.9 to 12.8) | 11.9 (8.0 to 13.0) |
| ng/mL | EDP-938 |
|---|---|
| Visit 1 - Postdose | 847.00 (0.0 to 5200.0) |
| Visit 2 - Predose | 926.00 (0.0 to 5060.0) |
| Visit 3 - Predose | 979.50 (0.0 to 4040.0) |
| Early Disc/EOS | 883.00 (366.0 to 1400.0) |
Number of subjects experiencing any Treatment-Emergent Adverse Events (TEAEs)
| Participants | EDP-938 | Placebo |
|---|---|---|
| Safety as Measured by Frequency of Adverse Events (AEs) | 27 | 16 |
PGI-S is a 7-point patient-reported scale ranging from 1 (normal/none) to 7 (among the most extremely ill); lower scores indicate less severe disease. Time to resolution is defined as time from the first dose to first of two consecutive timepoints where the response assessed by PGI-S is 'None'. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.
| Days | EDP-938 | Placebo |
|---|---|---|
| Time to Resolution of RSV Infection Symptoms by Patient Global Impression of Severity (PGI-S) Scale Score for the mITT Population | 9.0 (8.0 to 10.0) | 10.9 (9.0 to 15.0) |
Incidence was defined as the number of subjects with new antibiotic, bronchodilators, inhaled corticosteroids or oxygen use
| Participants | EDP-938 | Placebo |
|---|---|---|
| Incidence of New Antibiotic Use, or New or Increased Use of Bronchodilators, Systemic or Inhaled Corticosteroids, or Oxygen Supplementation for the mITT Population | 16 | 6 |
Incidence was defined as the number of subjects with unscheduled medically attended visits for RSV infection or other causes.
| Participants | EDP-938 | Placebo |
|---|---|---|
| Incidence of Unscheduled Medically Attended Visits for RSV Infection or Other Causes for the mITT Population | 8 | 4 |
The RiiQ Infection Intensity Scale assesses 4 lower respiratory, 2 upper respiratory, and 7 systemic symptoms on a scale of 0 (absent) to 3 (severe). The composite Total Symptom Score is the average of all 13 individual item scores.
| MMRM adjusted LS mean score | EDP-938 | Placebo |
|---|---|---|
| Day 2 | 1.213 ± 0.0420 | 1.209 ± 0.0561 |
| Day 3 | 1.072 ± 0.0464 | 1.061 ± 0.0622 |
| Day 5 | 0.713 ± 0.0446 | 0.723 ± 0.0597 |
| Day 7 | 0.452 ± 0.0468 | 0.569 ± 0.0620 |
| Day 9 | 0.320 ± 0.0443 | 0.470 ± 0.0586 |
| Day 14 | 0.194 ± 0.0369 | 0.331 ± 0.0493 |
| Day 33 | 0.083 ± 0.0224 | 0.095 ± 0.0302 |
The RiiQ Infection Intensity Scale assesses 4 lower respiratory, 2 upper respiratory, and 7 systemic symptoms on a scale of 0 (absent) to 3 (severe). The composite Total Symptom Score is the average of all 13 individual item scores.
| MMRM adjusted LS mean score | EDP-938 | Placebo |
|---|---|---|
| Day 2 | 1.208 ± 0.0377 | 1.172 ± 0.0514 |
| Day 3 | 1.049 ± 0.0428 | 1.001 ± 0.0587 |
| Day 5 | 0.695 ± 0.0397 | 0.686 ± 0.0543 |
| Day 7 | 0.456 ± 0.0415 | 0.517 ± 0.0563 |
| Day 9 | 0.332 ± 0.0387 | 0.425 ± 0.0523 |
| Day 14 | 0.211 ± 0.0333 | 0.300 ± 0.0454 |
| Day 33 | 0.069 ± 0.0183 | 0.078 ± 0.0253 |
| RSV viral load (log10 copies/mL) | EDP-938 | Placebo |
|---|---|---|
| Day 3 | -1.079 ± 0.2096 | -0.522 ± 0.2827 |
| Day 5 | -1.880 ± 0.2407 | -1.226 ± 0.3233 |
| Day 9 | -3.437 ± 0.2697 | -2.904 ± 0.3510 |
| Day 14 | -4.046 ± 0.2475 | -3.865 ± 0.3149 |
Complete resolution of total RiiQ scale score (Q1-29) is defined as the first of two consecutive timepoints where the score of each of the 29 questions is zero. Time to complete resolution (days) is calculated as: date/time of complete resolution - date/time of first dose.
| Days | EDP-938 | Placebo |
|---|---|---|
| Time to Complete Resolution of Total Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Scale Score for the mITT Population | 15.3 (12.2 to 19.5) | 18.9 (13.1 to 28.0) |
Complete resolution of total RiiQ scale score (Q1-29) is defined as the first of two consecutive timepoints where the score of each of the 29 questions is zero. Time to complete resolution (days) is calculated as: date/time of complete resolution - date/time of first dose.
| Days | EDP-938 | Placebo |
|---|---|---|
| Time to Complete Resolution of Total RiiQ Scale Score for the HR3 Population | 13.8 (11.9 to 19.9) | 21.0 (13.1 to NA) |
PGI-S is a 7-point patient-reported scale ranging from 1 (normal/none) to 7 (among the most extremely ill); lower scores indicate less severe disease. Time to resolution is defined as time from the first dose to first of two consecutive timepoints where the response assessed by PGI-S is 'None'. Time to resolution is calculated as: date/time of resolution - date/time of first dose with conversion to days.
| Days | EDP-938 | Placebo |
|---|---|---|
| Time to Resolution of RSV Infection Symptoms by PGI-S Scale Score for the HR3 Population | 9.0 (8.0 to 11.0) | 10.9 (9.0 to 16.0) |
| Participants | EDP-938 | Placebo |
|---|---|---|
| Day 1 | 4 | 3 |
| Day 3 | 14 | 4 |
| Day 5 | 22 | 5 |
| Day 9 | 44 | 18 |
| Day 14 | 52 | 27 |
Time to RSV viral load TND is defined as the time between the date of first dose to the first date of achieving viral load TND.
| Days | EDP-938 | Placebo |
|---|---|---|
| Time to RSV RNA Viral Load TND for the HR3 Population | 8.0 (7.8 to 13.0) | 12.9 (8.0 to 13.1) |
Collected over Adverse event data was collected beginning on Day 1 and concluded at the End-of-Study (EOS) visit on Day 33.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EDP-938 | 0/115 (0%) | 2/121 (1.7%) | 27/121 (22.3%) |
| Placebo | 1/60 (1.7%) | 4/65 (6.2%) | 16/65 (24.6%) |
| Event | EDP-938 | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 0/121 | 1/65 |
| Pneumonia bacterialInfections and infestations | 0/121 | 1/65 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/121 | 1/65 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/121 | 1/65 |
| Cardiac failure chronicCardiac disorders | 0/121 | 1/65 |
| Systemic inflammatory response syndromeGeneral disorders | 0/121 | 1/65 |
| Renal impairmentRenal and urinary disorders | 0/121 | 1/65 |
| InfluenzaInfections and infestations | 1/121 | 0/65 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/121 | 0/65 |
| Event | EDP-938 | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/121 | 1/65 |
| NauseaGastrointestinal disorders | 1/121 | 2/65 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/121 | 1/65 |
| AstheniaGeneral disorders | 2/121 | 0/65 |
| Glomerular filtration rate decreasedInvestigations | 2/121 | 0/65 |
| DysgeusiaNervous system disorders | 2/121 | 0/65 |
| DyspepsiaGastrointestinal disorders | 0/121 | 1/65 |
| Faeces softGastrointestinal disorders | 1/121 | 1/65 |
| HaemorrhoidsGastrointestinal disorders | 0/121 | 1/65 |
| BronchitisInfections and infestations | 0/121 | 1/65 |
Modified Intent-to-Treat (mITT) population: all randomized subjects positively diagnosed with RSV using the central RT-qPCR test who receive at least one dose of assigned study drug.
| Age, Continuous(years) | EDP-938 | Placebo | Total |
|---|---|---|---|
| Mean | 68.0 ± 14.29 | 68.1 ± 15.46 | 68.0 ± 14.66 |
| Sex: Female, Male(Participants) | EDP-938 | Placebo | Total |
|---|---|---|---|
| Female | 69 | 45 | 114 |
| Male | 46 | 15 | 61 |
| Ethnicity (NIH/OMB)(Participants) | EDP-938 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 72 | 29 | 101 |
| Not Hispanic or Latino | 43 | 31 | 74 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | EDP-938 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 4 | 2 | 6 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 11 | 2 | 13 |
| White | 98 | 54 | 152 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2022 to primary completion in Jun 2025, 30 months.
Results were first posted in Aug 2026, 1 year 1 month after primary completion.
Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 30 months is above that.
Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EDP-938
Respiratory Syncytial Virus Infections →